Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients

Current Medical Research and Opinion

Volumn 27, Issue 4, 2011, Pages 751-760

  Nalamachu, S R ^a   Narayana, A ^b   Janka, L ^b  

^a Mid America Physiatrists   (United States)

^b CEPHALON INC   (United States)

Author keywords

Breakthrough pain; Fentanyl buccal tablet; Long term safety; Longterm pain treatment; Opioids

Indexed keywords

FENTANYL; FENTANYL CITRATE; HYDROMORPHONE; MORPHINE; OPIATE; OXYCODONE; PLACEBO;

ADULT; AGE DISTRIBUTION; AGED; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE ULCER; ARTHRALGIA; ARTICLE; BACKACHE; BREAKTHROUGH PAIN; BRONCHITIS; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; LEG PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHIC PAIN; PAIN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; POPULATION RESEARCH; RHINOPHARYNGITIS; SEX DIFFERENCE; SINUSITIS; SOMNOLENCE; TABLET; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WITHDRAWAL SYNDROME;

ADMINISTRATION, BUCCAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CONTROLLED CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FENTANYL; HUMANS; MIDDLE AGED; PAIN; SEVERITY OF ILLNESS INDEX; TABLETS; TIME FACTORS; YOUNG ADULT;

EID: 79952689965     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.554808     Document Type: Article

References (37)

1. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
2. Martin BI, Deyo RA, Mirza SK, et al. Expenditures and health status among adults with back and neck problems. JAMA 2008;299:656-64 (Pubitemid 351252723)
3. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-54 (Pubitemid 37430544)
4. Chou R, Ballantyne JC, Fanciullo GJ, et al. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10:147-59
5. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996;11:203-17 (Pubitemid 26102522)
6. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81 (Pubitemid 20187930)
7. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;94:832-9 (Pubitemid 34132314)
8. Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;18:177-83 (Pubitemid 38771657)
9. Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006;7:583-91 (Pubitemid 44137488)
10. Portenoy RK, Bruns D, Shoemaker B, et al. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag 2010;6:97-108
11. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005;9:195-206 (Pubitemid 40311842)
12. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34 (Pubitemid 29199908)
13. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 2006;CD004311
14. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003;101:55-64 (Pubitemid 36044654)
15. Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Deliv 2006;4:1-5
16. Messina J, Darwish M, Fine PG. Fentanyl buccal tablet. Drugs Today (Barc) 2008;44:41-54 (Pubitemid 351397412)
17. Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-11 (Pubitemid 44627444)
18. Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5:327-34 (Pubitemid 350055013)
19. Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a longterm, open-label safety study. Cancer 2009;115:2571-9
20. Portenoy RK, Messina J, Xie F, et al. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 2007;23:223-33 (Pubitemid 46191684)
21. Simpson DM, Messina J, Xie F, et al. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:588-601 (Pubitemid 47016640)
22. Farrar JT, Messina J, Xie F, et al. A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain. Pain Med 2010;11:1313-27
23. Fine PG, Messina J, Xie F, et al. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. J Pain Symptom Manage 2010;40:747-60
24. Webster LR, Messina J, Xie F, et al. Effects of fentanyl buccal tablet (FBT) on pain anxiety symptoms in the management of breakthrough pain in opioidtolerant patients with chronic pain: a 4-week open-label study [in preparation] 2011
25. Passik SD, Messina J, Golsorkhi T, et al. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. J Pain Symptom Manage 2010 Jun 24 [E-pub ahead of print]
26. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain 2004;109:514-19
27. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain 2006;7:225-35
28. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010;CD006605
29. Allan L, Richarz U, Simpson K, et al. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Spine (Phila Pa 1976) 2005;30:2484-90
30. Kalso E, Simpson KH, Slappendel R, et al. Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine. BMC Med 2007;5:39
31. Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 2007;23:117-28 (Pubitemid 46191677)
32. Murphy K, Zeiher B, Herman B, et al. Long-term safety and tolerability of pregabalin treatment in three open-label extension studies in patients with fibromyalgia. J Pain 2009;10(4; Suppl 1):S58
33. Mystakidou K, Parpa E, Tsilika E, et al. Long-term management of noncancer pain with transdermal therapeutic system-fentanyl. J Pain 2003;4:298-306 (Pubitemid 37013020)
34. Portenoy RK, Farrar JT, Backonja M-M, et al. Long-term use of controlledrelease oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain 2007;23:287-99 (Pubitemid 46650020)
35. Rauck RL, Bookbinder SA, Bunker TR, et al. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag 2006;2:155-66
36. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44
37. Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10:131-46